GSK and Roche Korea jointly to launch once-a-month anti-osteoporosis drug.

Published: 2006-08-24 07:00:00

Updated: 2006-08-24 07:00:00

Roche Korea and GSK took the KFDA approval of "Bonviva 150mg tab" (ibandronate), just administering once a month, which is the first dosage form of once a month administration in Korea for the treatment of the post menopause osteoporosis. It may be launched into the local market during the 1/4 of...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK